


**Product Name** : NIBR-LTSi  
**Cat. No.** : PC-22068  
**CAS No.** :  
**Molecular Formula** : C<sub>18</sub>H<sub>20</sub>N<sub>4</sub>O  
**Molecular Weight** : 308.39  
**Target** : Hippo  
**Solubility** : 10 mM in DMSO



## Biological Activity

NIBR-LTSi is a potent, highly selective and orally active **LATS kinase** inhibitor with IC<sub>50</sub> of 1.4 nM in biochemical CALIPER assay, potently reduces pYAP levels with IC<sub>50</sub> of 2.16 μM in JHH5 cells.

NIBR-LTSi robustly reduces YAP phosphorylation and increases proliferation in wild-type (WT) HEK293A cells but not in HEK293A cells with LATS kinase deletion.

NIBR-LTSi (10 μM) promotes primary keratinocyte expansion and blocks differentiation in human 3D skin model.

NIBR-LTSi promotes liver organoid formation (EC<sub>50</sub>=0.35 μM) and hepatocyte proliferation, NIBR-LTSi-induced YAP signaling enables BEC organoid formation and growth in the absence of WNT/β-catenin-inducing agents.

NIBR-LTSi promotes YAP/TAZ-dependent hepatocyte proliferation and accelerates liver regrowth in AAV8-induced YAP/TAZΔHEP.

NIBR-LTSi induces proliferation of kidney TECs, promotes ISC expansion and blocks their differentiation in organoids and in vivo, accelerates liver regeneration, following partial and extended hepatectomy.

## References

Namoto K, et al. *Cell Stem Cell*. 2024 Apr 4;31(4):554-569.e17.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com